These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Amyloid-beta decreases cell-surface AMPA receptors by increasing intracellular calcium and phosphorylation of GluR2. Liu SJ; Gasperini R; Foa L; Small DH J Alzheimers Dis; 2010; 21(2):655-66. PubMed ID: 20571220 [TBL] [Abstract][Full Text] [Related]
27. Neurodegeneration. Potential Alzheimer's drug spurs protein recycling. Garber K Science; 2014 Apr; 344(6182):351. PubMed ID: 24763565 [No Abstract] [Full Text] [Related]
28. [Glutamate- and Gaba-mediated extrasynaptic diffuse signaling in the hippocampus]. Sem'ianov AV Zh Vyssh Nerv Deiat Im I P Pavlova; 2004; 54(1):68-84. PubMed ID: 15069817 [TBL] [Abstract][Full Text] [Related]
30. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Almeida CG; Tampellini D; Takahashi RH; Greengard P; Lin MT; Snyder EM; Gouras GK Neurobiol Dis; 2005 Nov; 20(2):187-98. PubMed ID: 16242627 [TBL] [Abstract][Full Text] [Related]
31. Cdk5-Foxo3 axis: initially neuroprotective, eventually neurodegenerative in Alzheimer's disease models. Shi C; Viccaro K; Lee HG; Shah K J Cell Sci; 2016 May; 129(9):1815-1830. PubMed ID: 28157684 [TBL] [Abstract][Full Text] [Related]
32. Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents. Qi Y; Klyubin I; Harney SC; Hu N; Cullen WK; Grant MK; Steffen J; Wilson EN; Do Carmo S; Remy S; Fuhrmann M; Ashe KH; Cuello AC; Rowan MJ Acta Neuropathol Commun; 2014 Dec; 2():175. PubMed ID: 25540024 [TBL] [Abstract][Full Text] [Related]
33. Induction of beta-amyloid-containing polypeptides in hippocampus: evidence for a concomitant loss of synaptic proteins and interactions with an excitotoxin. Bahr BA; Abai B; Gall CM; Vanderklish PW; Hoffman KB; Lynch G Exp Neurol; 1994 Sep; 129(1):81-94. PubMed ID: 7925845 [TBL] [Abstract][Full Text] [Related]
34. Predominant loss of glutamatergic terminal markers in a β-amyloid peptide model of Alzheimer's disease. Canas PM; Simões AP; Rodrigues RJ; Cunha RA Neuropharmacology; 2014 Jan; 76 Pt A():51-6. PubMed ID: 24029236 [TBL] [Abstract][Full Text] [Related]
35. Neuronal amyloid-β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease. Baker-Nigh A; Vahedi S; Davis EG; Weintraub S; Bigio EH; Klein WL; Geula C Brain; 2015 Jun; 138(Pt 6):1722-37. PubMed ID: 25732182 [TBL] [Abstract][Full Text] [Related]
36. Early neuronal loss and axonal/presynaptic damage is associated with accelerated amyloid-β accumulation in AβPP/PS1 Alzheimer's disease mice subiculum. Trujillo-Estrada L; Dávila JC; Sánchez-Mejias E; Sánchez-Varo R; Gomez-Arboledas A; Vizuete M; Vitorica J; Gutiérrez A J Alzheimers Dis; 2014; 42(2):521-41. PubMed ID: 24927710 [TBL] [Abstract][Full Text] [Related]